Allergan and tribe claim PTAB can’t decide on Restasis patents

Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board (PTAB) doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit agrees with PTAB in optical patent appeal

21 January 2021 The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.

Americas

Allergan and tribe to appeal PTAB’s immunity decision

2 March 2018 The Saint Regis Mohawk Tribe and Allergan are planning to appeal against the Patent Trial and Appeal Board’s decision rejecting tribal sovereign immunity.

Americas

Native American tribe not entitled to sovereign immunity: PTAB

26 February 2018 The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

More features

MSD scores second win in patent fight over Keytruda

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Allergan and tribe claim PTAB can’t decide on Restasis patents

More on this story

Editor's picks

Editor's picks

More features